Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD

Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD

Gastrointestinal intolerance has been associated with ritonavir-boosted protease inhibitors. This post hoc analysis evaluated gastrointestinal adverse events of interest (AEOIs; diarrhea, nausea, abdominal discomfort, flatulence [MedDRAv21]) through Wk96 among patients enrolled in the phase 3 AMBER...

Full description

Bibliographic Details
Main Authors: Keith Dunn, Bryan Baugh, Nika Bejou, Donghan Luo, Jennifer Campbell, Sareh Seyedkazemi, David Anderson
Format: Article
Language:English
Published: SAGE Publishing 2022-04-01
Series:Journal of the International Association of Providers of AIDS Care
Online Access:https://doi.org/10.1177/23259582221088202

Similar Items

Similar Items